Doctor of Osteopathy Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Peter Liu

Urology East Lansing, MI Doctor of Osteopathy

NPI 1134509987 CMS profile 1363217

1625 Ramblewood Dr Ste 1, East Lansing, MI 48823

Open in the dashboard

General payments

$2,230

47 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Peter Liu of East Lansing, MI is reported in the CMS Open Payments database as having received $2,230 across 47 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 46th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $22 1
2021 General $1,554 39
2020 General $406 4
2019 General $249 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Peter Liu
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Peter Liu were reported at $0. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Peter Liu Urology median Middle half National median
2019 $249 $480 $147–$1,201 $163
2020 $406 $246 $87–$645 $114
2021 $1,554 $358 $111–$1,000 $132
2022 $0 $476 $143–$1,263 $149
2023 $22 $560 $168–$1,461 $160
2024 $0 $563 $170–$1,464 $164
2025 $0 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Axonics Modulation Technologies, Inc. $1,029 16 payments
  2. Cook Incorporated $367 1 payment
  3. PROCEPT BioRobotics Corporation $250 2 payments
  4. Boston Scientific Corporation $152 4 payments
  5. Coloplast Corp $86 2 payments
  6. Allergan Inc. $62 4 payments
  7. AstraZeneca Pharmaceuticals LP $32 2 payments
  8. Janssen Scientific Affairs, LLC $31 1 payment
  9. Clarus Therapeutics Inc. $29 2 payments
  10. Janssen Biotech, Inc. $26 2 payments
  11. Other $167 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $1,359 43 payments
  2. Travel and Lodging $852 3 payments
  3. Education $19 1 payment
Products named General payments · program years 2019–2023
  1. Axonics r-SNM System $1,006 15 payments
  2. Bulkamid $797 9 payments
  3. Cook Medical Dilation/Access $367 1 payment
  4. AQUABEAM ROBOTIC SYSTEM Urology $133 1 payment
  5. AMS $118 2 payments
  6. AQUABEAM ROBOTIC SYSTEM Urology $117 1 payment
  7. Titan $86 2 payments
  8. ERLEADA $57 3 payments
  9. BOTOX $43 3 payments
  10. JATENZO $29 2 payments
  11. Other $405 26 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

1,222

Median for Urology: 1,053

Drug cost

$70,779

Median for Urology: $101,464

Branded share of claims

22.9%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 47 $47,308
Tamsulosin Hcl Generic 423 $6,553
Finasteride Generic 179 $3,711
Oxybutynin Chloride Er Oxybutynin Chloride Brand 95 $2,688
Estradiol Generic 18 $1,948
Fosfomycin Tromethamine Generic 12 $1,928
Potassium Citrate Er Potassium Citrate Brand 12 $1,133
Cephalexin Generic 134 $1,083
Trimethoprim Generic 13 $985
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 28 $548

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$55,603

Medicare's payments for the services billed

Medicare patients

217

Average age 76

Services billed

780

61 women, 156 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Chronic kidney disease 38%
Diabetes 36%
Ischemic heart disease 35%
Atrial fibrillation 31%
Heart failure 29%
COPD 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

47 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record